Journal Guide

The International Journal for Parasitology – Drugs and Drug Resistance publishes the results of original research in the area of anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal also covers research into natural products as anti-parasitic agents, and bioactive parasite products. Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.A list showing the types of articles that are considered is included below. Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. Because of its breadth of organism coverage, all contributions should include relevant information about the parasite of interest in order to be comprehensible to non-experts in the particular subject of the articles. The principal form of publication is the full length article which contains substantial results from a major program of research. The journal also accepts brief reports that have similar subject scope as the full-length article, but do not merit a full-length publication.In addition, the journal provides a medium for highlighting selected articles reporting highly significant original findings, as Editor's Choice Manuscripts. It also commissions articles with emphasis on shorter, focused Reviews of topical issues and strategically important subjects. The journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions".This title is fully open access and therefore funded not through library subscription payments but through author fees. If you would like your article to be published open access, but you genuinely cannot afford these fees, then individual waiver requests are considered on a case-by-case basis and may be granted in cases of genuine need. Priority for this waiver programme will be given to applications by authors from countries eligible for the Research4Life programme (see http://www.research4life.org/institutions.html).Types of articles considered:Compound library screening for inhibitors against enzymes or whole parasitesDrug target validation (chemical and/or genetic)Drug target identification (must include some inhibitor studies rather than characterisation of an enzyme, for example)Drug structure-activity relationship studiesMechanisms of drug action and resistanceReports of the development of drug resistance both in the field and laboratoryStudies on drug toxicity to the host (either on single host cells or whole organism)Reports on toxicity in the fieldComputational approaches to drug discovery or drug-target identificationDevelopment of assays directed at screening for inhibitorsDrug combination studiesNatural products as anti-parasitic agentsBioactive products produced by parasitesUse of live parasites as immunomodulatory agentsEpidemiological aspects of the emergence and spread of parasite drug resistanceHuman clinical trials

The online-version will be updated every month before the print-version of the Clinical Nephrology will be published. Upon request we will send the password and user name by e-mail. The online-service is only available for subscribers of the print-version, if proof of purchase is submitted. The use of the online-version will be charged with an extra fee (additional to the subscription of the print-version). The service can be used until December 31st of the year of subscription.

This is a transformative journal, you may have access to funding.

The rapid growth of interest in medicinal mushrooms research is matched by the large number of disparate groups that currently publish in a wide range of publications. The International Journal of Medicinal Mushrooms is the one source of information that will draw together all aspects of this exciting and expanding field - a source that will keep you up to date with the latest issues and practice. The International Journal of Medicinal Mushrooms published original research articles and critical reviews on a broad range of subjects pertaining to medicinal mushrooms, including systematics, nomenclature, taxonomy, morphology, medicinal value, biotechnology, and much more. Papers on new techniques that might promote experimental progress in the aforementioned field are also welcomed. In addition to full-length reports of original research, the journal publishes short communications and interesting case reports, together with literature reviews. Letters to the editor on topics of interest to readers are also published.

clinical application, or which provides insights into the biological basis of neuropsychiatric disorders and thereby advances their pharmacological treatment. Such research might derive from the full spectrum of biological and psychological fields of inquiry, encompassing classical and novel techniques in neuropsychopharmacology, as well as strategies such as neuroimaging, genetics, psycho-neuroendocrinology and neuropsychology. IJNP's rapid publication policy is facilitated by web-based submission and review, and the journal publishes the definitive versions of papers online, ahead of the printed issues. All papers are indexed in PubMed and Thomson Reuters Journal Citation Reports.

International Journal of Pharmacology is a peer-reviewed well indexed scientific journal dedicated to publish the significant research findings in all areas of pharmacology and related disciplines. Scope of the journal covers: behavioral pharmacology, neuro-pharmacology and analgesia, cardiovascular pharmacology, pulmonary, gastrointestinal and urogenital pharmacology, endocrine pharmacology, immune-pharmacology and inflammation and molecular and cellular pharmacology. International Journal of Pharmacology now accepting new submissions. Submit your best paper via online submission system.

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.

Investigatio

Journal for ImmunoTherapy of Cancer is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.The journal welcomes submissions in the following areas and other related topics:Basic Tumor ImmunologyTumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions with the anti-tumor immune responseClinical/Translational Cancer ImmunotherapyFirst-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcomeImmunotherapy BiomarkersPredictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studiesReviews/EditorialsTriggering discussion on hot topics and innovative concepts

Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC). The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The society has become THE forum for innovative discussions in the field.

Discover the latest in basic and applied research in the analytical sciences related to foods, drugs, agriculture, and the environment. Read contributions from leaders in the fields of chemical and biological analysis, original collaborative studies of AOAC Official MethodsSM, special guest editor sections, invited reviews, and much more.The Journal of AOAC INTERNATIONAL publishes 6 issues per year of fully refereed contributed papers in the fields of chemical and biological analysis: on original research on new techniques and applications, collaborative studies, authentic data of composition, studies leading to method development, meeting symposia, newly adopted AOAC approved methods and invited reviews. To view Journal table of contents and abstracts, click here. (You will be redirected to Atypon, our online host.).

The Journal of Antimicrobial Chemotherapy is among the foremost international journals in antimicrobial research. Our readership includes representatives of academia, industry and health services, and includes those who are influential in formulary decisions.Published monthly, the Journal features original articles on the laboratory aspects and clinical use of antimicrobials including antibacterial, antiviral, antifungal, and antiprotozoal agents.In addition to the wealth of primary papers, the journal carries review articles offering in-depth discussion on matters of topical concern. Lively leading articles offer incisive coverage of recent advances and controversies.Other sections include: * For debate: International comment on contentious issues and ideas * Antimicrobial practice: Articles on practical prescribing and formulary issues * Correspondence: A section for scientists to present early observations of their work and to comment on published articles * Book reviews: Helpful reviews of relevant, newly published titles A carefully organised format directs you to areas of interest.Monthly issues can include up to ten informative sections: * Leading articles * Reviews * The Garrod Lecture * For debate * Original articles * Brief reports * Antimicrobial practice * Meeting reports * Correspondence * Book reviews The Journal publishes between two and eight supplements each year. These include Working Party reports of the British Society for Antimicrobial Chemotherapy, and original publications on pre-clinical and clinical aspects of drugs in development or the role of established drugs in specific therapeutic areas.

The Journal of Asian Natural Products Research (JANPR) publishes chemical and pharmaceutical studies in the English language in the field of natural product research on Asian ethnic medicine. The journal publishes work from scientists in Asian countries, e.g. China, Japan, Korea and India, including contributions from other countries concerning natural products of Asia. The journal is chemistry-orientated. Major fields covered are: isolation and structural elucidation of natural constituents (including those for non-medical uses), synthesis and transformation (including biosynthesis and biotransformation) of natural products, pharmacognosy, and allied topics. Biological evaluation of crude extracts are acceptable only as supporting data for pure isolates with well-characterized structures.All published research articles in this journal have undergone rigorous peer review, based on initial editor screening and anonymized refereeing by at least two expert referees. STARTaylor & Francis/Routledge are committed to the widest possible dissemination of its journals to non-profit institutions in developing countries. Our STAR initiative offers individual researchers in Africa, South Asia and many parts of South East Asia the opportunity to gain one month's free online access to 1,300 Taylor & Francis journals. For more information, please visit the STAR website. DisclaimerTaylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in its publications. However, Taylor & Francis and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether express or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not the views of Taylor & Francis.

The Journal of Biomolecular Screening (JBS) is the leading peer-reviewed journal focusing on drug discovery sciences. JBS publishes information that enables researchers to evaluate current technologies and incorporate applications to enhance performance and objectives. Manuscripts and editorial commentary emphasize scientific and technical applications and advances in target identification/validation; lab automation and robotics; high-throughput screening (HTS); lead generation/optimization; virtual screening, chemoinformatics; diagnostic assays; assay development; assay technologies (novel applications, comparisons); data/image analysis, statistics and information technologies/methods; high content screening, imaging platforms; sample management (library design, compound logistics, chemical diversity); biological reagent production, characterization and management for drug discovery (cell lines, stem cells, surrogate tissues/species [xenopus, zebrafish, yeast]); genomic, proteomic screening; biomarkers; high throughput approaches to PK, ADME and predictive toxicology; legal, licensing issues.This publication will be of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.

The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to such work in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: * drug, device, and biological research and development * drug screening and drug design * assessment of pharmacological activity * pharmaceutical formulation and scale-up * preclinical safety assessment * bioavailability, bioequivalence, and pharmacokinetics * phase, I, II, and III clinical development * premarket approval assessment of clinical safety * postmarketing surveillance Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.

The Journal of Cardiovascular Pharmacology is the leading publication devoted exclusively to important advances in cardiovascular drug research and use. Each monthly issue provides the most up-to-date information on physiological and pharmacological bases of drug action, metabolism, drug interaction, side effects, and clinical results with both new and established drugs.Website: www.jcvp.org.

DON'T MISS A BEAT!Every informative issue of the Journal of Cardiovascular Pharmacology and Therapeutics (JCPT) offers cardiologists, clinical pharmacologists and researchers involved in disease relevant clinical and experimental investigations of newer cardiovascular drugs and other therapeutic options. Four times a year, JCPT examines and analyzes arenas such as: o Agents that Reduce Myocardial Infarct Size o Agents that Reduce Myocardial Remodeling o Angiotensin Converting Enzyme Inhibitors o Antihypertensive Therapy o Arrhythmias o Atrial Fibrillation o Beta-Blocker Therapies o Cardioembolic Stroke o Cardiomyopathy o Cardioprotective Agents o Cardiopulmonary Resuscitation o Cardiovascular Combination Therapies o Chronic Angina o Chronic Cardiac Ischemia o Congestive Heart Failure o Coronary Artery Disease o Coronary Revascularization o Heparin Therapies o Hypertension o Hypotension o Implantable Devices o Ischemic Heart Disease o Myocardial Infarction o Percutaneous Coronary Interventions o Peripheral Arterial Disease o Preconditioning/Postconditioning o Regenerative Cardiology o Stem Cell TherapyAmong the drug classes regularly evaluated are: ACE inhibitors * angiotensin receptor blockers * anti-anginals * anti-arrhythmics * anti-coagulants * anti-hypertensives * anti-thrombins * beta-blockers * calcium channel blockers * cardioprotective agents * cardiotonic agents * direct renin inhibitors * diuretics * fibrinolytic agents * heart rate modulats * plasminogen activators * QT prolonging drugs * statins * vasoconstrictor agents * and vasodilator agents.The journal features original articles, topical journal supplements, reviews, clinical and experimental investigations, and commentaries written by respected practitioners from all over the world.